Prospective observational study on relationship between plasma-free amino acids profiles and risk of mild cognitive impairment, including future risk of Alzheimer's disease onset

Prospective observational study on relationship between plasma-free amino acids profiles and risk of mild cognitive impairment, including future risk of Alzheimer's disease onset - Observational study on plasma-free amino acids profiles in mild cognitive impairment (MCI) cohort

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000021965

Enrollment

600

Registered

2016-04-29

Start date

2016-04-29

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mild Cognitive Impairment (MCI), Alzheimer&#39

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Not be 'probable AD' with NINCDS-ADRDA (The National Institute od Neurologic, Communicatibve Disorders and Stroke AD and Related disorders Association) criteria. MMSE (Mini Mental State Examination) score is between 24 to 30 points. (Additional entry criteria for MCI subjects are described below.) WMS-R LMII (Wechsler Memory Scale-Revised Logical Memory) score is less than 11, 9, or 6 points (with schooling history for more than 16 years, 8-15 years, 0-7 years, respectively).Or score of CDR(Clinical Dementia Rating) is 0.5. Score of GDS-J (Geriatric Depression Scale-Japanese version) is less than 6 points. Possible to obtain agreement of participation in the trial from subject himself/herself or legal representative.

Exclusion criteria

Exclusion criteria: Subjects who have taken any amino acid-formulations, supplements, and bevarage within 10 hours before the blood collection. Subjects who have taken meals within 10 hours before the blood collection. Subjects who have been educated for less than 6 years. Subjects who have previous history or are under medical treatment for alcohol addiction. Patients of cancer or cirrhosis of liver. Dialysis patients Subjects who developed other neurodegenerative or mental disorders. In addition to above, subjects who are judged as ineligible by the medical doctors who are responsible for this trial as investigators.

Design outcomes

Primary

Measure	Time frame
Plasma-free amino acids and related metabolites	—

Secondary

Measure	Time frame
Results of neuropsychological tests Results of diagnostic imaging Onset of Alzheimer's disease APOE4 allele	—

Countries

Japan

Contacts

Public ContactHitomi Kitamura

Ajinomoto Co., Inc. Aminoindex&Supportive Care Group, Research Institute For Biosciences&Fine Chemicals

hitomi.kitamura01.mx9@asv.ajinomoto.com+81-44-210-5835

Outcome results